Why people actually stop, in the order they actually stop
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Patient Notes
Page 5 of 25 of this archive, newest first.
Page 5
Poland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Why your laboratory interval differs from the one in the textbook
Two sources of noise sit under every number: how reproducible the assay is, and how much the analyte varies within the same person on the same day.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
When to stop escalating and when to stop entirely
We set out the questions that distinguish a symptom to manage from a dose to change.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new South Africa guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Australia pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
What happens when the drug is taken away: three randomised answers
What was withdrawn, from whom, after how long, and what was measured afterwards.
The ceiling is a tolerability finding, not an efficacy one
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
What the new South Korea guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Reading the retatrutide composition data without the press release
The trials measured mass. Nobody measured whether the participants got weaker.
Spain pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A reference interval is not a target, and a result outside one is not a diagnosis
The arithmetic of the reference change value, worked for the analytes that matter here.
Argentina pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The intramuscular injection nobody intended
Longer needles reach muscle in lean limbs, and intramuscular delivery of a long-acting depot changes absorption in ways nobody wants.
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Mexico pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.